Cambridge, Mass. – – October 02, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 1, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its September 29, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Cambridge, Mass. – September 25, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.